women desperate to piss ava addams mom porn sa akin ang gabi

Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

Summit Receives Fast Track Designation from US FDA for Ezutromid

<p>26 September 2016: Oxford, UK.  Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and <i>Clostridium difficile</i> infection, today announces it has received Fast Track designation from the US Food and Drug Administration ('FDA') for ezutromid in the treatment of DMD. Ezutromid is a utrophin modulator and represents a potential disease modifying treatment for all patients with the fatal muscle wasting disease DMD.</p>

Read the rest of entry »

PCI to Share Expertise in Serialization and Safe Handling of Potent Molecules at CPHI Worldwide

20 September 2016: Philadelphia, USA – Leading pharmaceutical provider PCI Pharma Services will bring its expertize to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) with two Speakers Corner slots at the ICSE Exhibitor Showcase.

Read the rest of entry »

Wickham Labs to Exhibit at Medtec Ireland 2016

22 September 2016: Gosport, UK - Wickham Laboratories Ltd will exhibit on Stand 305 at Medtec Ireland, October 4-5.

Read the rest of entry »

Physiomics Placing and Update on Acquisition

21 September 2016 - Physiomics announces that it has completed a placing, conditional only on Admission, to raise £555,000.00 from the issue of 2,220,000,000 new ordinary shares of 0.004p each ("Ordinary Shares") at a price of 0.025p per share, through Hybridan LLP (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealing is expected to commence on 28th September 2016.

Read the rest of entry »

New Heparan Sulfate Antibodies Applications Guide

20 September 2016: Abingdon, UK - AMSBIO has produced a new 24-page guide that brings together applications, protocols, results and citations to provide an informative resource for researchers using heparan sulfate antibodies.

Read the rest of entry »

SynbiCITE Announces 4-day MBA for Future Biotechnology Leaders

19th September 2016: London, UK - SynbiCITE, in association with the Industrial Biotechnology Innovation Centre (IBiolC) will run another of its 4-Day MBA courses for biotech entrepreneurs in Glasgow from 20-24 November. This interactive course will cover key strategies required to establish, build and manage a biotechnology company and aid in developing the entrepreneurship of future leaders.

Read the rest of entry »

Wickham Laboratories Now Offering Stability Storage & Testing

19 September 2016: Gosport, UK - Wickham Laboratories is pleased to introduce  stability storage and testing as its latest service offering.

Read the rest of entry »

Local HealthScience Consultancy Welcomes Ed Vaizey MP

16 September 2016: Tubney, UK - The Right Honourable Edward Vaizey, local MP for Wantage, visited award-winning HealthScience communications consultancy Oxford PharmaGenesis to discuss the implications of Brexit for trade, education, research and health funding in Oxfordshire.  In light of the recent referendum, Oxford PharmaGenesis, an independent international consultancy headquartered in Oxford, now faces new opportunities and challenges that will impact on its business and that of its clients.

Read the rest of entry »

Immunocore Ranked in the Sunday Times Hiscox Tech Track 100

12 September 2016: Oxford, UK - Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, today notes that it has been ranked fourth overall in the 16th annual Sunday Times Hiscox Tech Track 100.

Read the rest of entry »

MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium difficile-associated Diarrhoea (CDAD) for MGB-BP-3

12 September 2016: Glasgow, UK – MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces today that the US Food and Drug Administration (FDA) has granted MGB-BP-3, MGB Biopharma’s lead product, Qualified Infectious Disease Product (QIDP) designation for the Treatment of Clostridium difficile-associated Diarrhoea (CDAD).

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
izmir sınırsız escort Betboo
konak escort alsancak escort side escort antalya grup escort antalya grup escort ankara rus escort
izmir eskort
casino metropol casinomaxi discount casino
dikmen escort eryaman escort alanya sınırsız escort belek escort
en iyi bahis siteleri yatırımsız deneme bonusu youwin mobilbahis bets10